|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
|
|
|
3.3 PRÉVENTION - VACCINS
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
Illumina & PacBio Throw In The Towel [Omics! Omics!]
|
|
|
|
|
|
PacBio also needs to take a hard look at all the applications it is used for and assess which are likely to yield serious growth and also which are most vulnerable to being upended by competition. For example, Iso-Seq mRNA sequencing has been quite popular and generating publications -- but it also is at huge risk of being taken over by Oxford Nanopore, as it is an application in which base perfect accuracy may be very secondary.
|
|
|
|
|
|
|
|
|
|
4.5 DÉP., DIAG. & PRONO. - COLORECTAL
|
|
|
|
Machine learning accurate at colorectal cancer diagnosis, may also predict survival [UPI]
|
|
|
|
|
|
According to Luo, their technology works by screening for methylation markers, which are DNA modifications that are frequently found in tumors. To test the approach, they created a diagnostic model based on nine methylation markers associated with colorectal cancer, which they identified by studying plasma samples from 801 people with colorectal cancer, as well as 1,021 healthy controls.
|
|
|
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
AI shows promise for breast cancer screening [Nature]
|
|
|
|
|
|
Could artificial intelligence improve the accuracy of screening for breast cancer? A comparison of the diagnostic performance of expert physicians and computers suggests so, but the clinical implications are as yet uncertain.
|
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
Milestone for Biopharmaceuticals in China [Boehringer Ingelheim]
|
|
|
|
|
|
Through its collaboration with BeiGene, Ltd. and the provision of manufacturing services for their monoclonal antibody tislelizumab, Boehringer Ingelheim Biopharmaceuticals China is the first company to successfully apply the adopted Marketing Authorization Holder (MAH) system within the revised Chinese Drug Administration Law (DAL).
|
|
|
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
New year, new (higher) drug prices [EndPoints]
|
|
|
|
|
|
Bristol-Myers, which swallowed Celgene in a $74 billion deal last year, also increased the prices of 10 drugs on Wednesday, including a 1.5% hike on its immunotherapies Opdivo and Yervoy.
|
|
|
|
|
|
|
6.10 POLITIQUES
|
|
|